. Author manuscript; available in PMC: 2009 Aug 15.

Published in final edited form as: Cancer. 2008 Aug 15;113(4):733–742. doi: 10.1002/cncr.23601

TABLE 3.

Immunohistochemistry for Mismatch-Repair Protein Expression in Unselected Ovarian Cancers

Reference	Location	Study Design	Sample Size	No. With MMR Loss (%)	Proteins Investigated	Method	Comments
Geisler 2003¹¹	Holden Comprehensive Cancer Center (Iowa)	Hospital-based	107	10 (9.3)	MLH1, MSH2, MSH3, MSH6, PMS1, PMS2	RT-PCR	No tumors without MSI-H had loss of MMR protein expression
Malander 2006⁴⁷	Lund University Hospital (Sweden)	Hospital-based	128	3 (2.3)	MLH1, MSH2, MSH6, PMS2	IHC on TMAs	All tumors with loss of MMR protein expression had MSI-H
Rosen 2006⁷⁵	M. D. Anderson Cancer Center (Tex)	Hospital-based	322	7 (2.2)	MLH1, MSH2	IHC on TMAs	-
Domanska 2007⁷³	Lund University Hospital/Swedish Cancer Registry (Sweden)	Population-based, age <40 y	98	6 (6.1)	MLH1, MSH2, MSH6, PMS2	IHC on full section	Five of 6 tumors with loss of MMR protein expression had MSI-H

MMR indicates mismatch-repair; MLH, mutL homolog; MSH, mutS homolog; PMS, postmeiotic segregation increased; RT-PCR, reverse transcriptase-polymerase chain reaction; MSI-H, high-level microsatellite instability; IHC, immunohistochemistry; TMAs, tissue microarrays.